Ovid Therapeutics
2014
FOUNDED
PUBLIC
STATUS
41-50
EMPLOYEES
OVID
STOCK SYMBOL
$2.56
SHARE PRICE
(As of Monday Closing)
Description
Ovid Therapeutics Inc is a US based biopharmaceutical company. The firm is engaged primarily in developing impactful medicines for patients and families living who are suffering with rare neurological disorders. It is targeting disorders such as intellectual disability, severe speech impairment, problems with movement and balance, sleep disorders and anxiety to transform the patient's life.
Primary Industry
Drug Discovery
Stock Exchange
NAS
Primary Office
- 1460 Broadway
- Suite 15021
- New York, NY 10036
- United States
+1 (646) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Ovid Therapeutics’s full profile, request a free trial.
Ovid Therapeutics Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $1.53 - $5.67 | $122M | $2.55 | -$1.73 | 620K | 47.8M |
Ovid Therapeutics Financials Summary
|
In Thousands,
USD |
TTM
30-Sep-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 73,915 | 7,155 | 146,792 | |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (57,011) | (52,790) | (64,927) | (22,479) |
| Net Income | (56,392) | (51,980) | (64,806) | (22,414) |
| Total Assets | 40,694 | 47,650 | 89,458 | 53,028 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Ovid Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Ovid Therapeutics‘s full profile, request access.
Request full access to PitchBookOvid Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is reserved for PitchBook Platform users. To explore Ovid Therapeutics‘s full profile, request access.
Request full access to PitchBookOvid Therapeutics Competitors (12)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Minerva Neurosciences | Formerly VC-backed | Waltham, MA | 00 | 00000 | 00000000 | 00000 |
| 00000000 000000000 | Formerly VC-backed | Coral Gables, FL | 00 | 000.00 | 00000000 | 000.00 |
| 0000000000 0000000 | Formerly VC-backed | Toronto, Canada | 00 | 000.00 | 000000&0 | 000.00 |
| 000000000 | Venture Capital-Backed | New York, NY | 000.00 | 00000000000 | 000.00 | |
| 0000000 | Venture Capital-Backed | CA | 000.00 | 00000000000 | 000.00 |
Ovid Therapeutics Executive Team (13)
5 Former Executives
You’re viewing 5 of 13 executives. Get the full list »Ovid Therapeutics Board Members (6)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Bart Friedman JD | Self | Board Member | 000 0000 | |
| Douglas Williams Ph.D | Self | Board Member | 000 0000 | |
| Howard Federoff Ph.D | Ovid Therapeutics | Chairman, Scientific Advisory Board | 000 0000 | |
| Jeremy Levin Ph.D | Ovid Therapeutics | Chief Executive Officer & Chairman | 000 0000 | |
| Karen Bernstein Ph.D | Self | Board Member | 000 0000 |
1 Former Board Member
You’re viewing 5 of 6 board members. Get the full list »